Search

Your search keyword '"Untch, M."' showing total 1,452 results

Search Constraints

Start Over You searched for: Author "Untch, M." Remove constraint Author: "Untch, M."
1,452 results on '"Untch, M."'

Search Results

53. Adjuvante Therapierealität bei Patienten mit einem primären Mammakarzinom: Eine retrospektive Registerstudie zur Bewertung der endokrinen Therapie-Strategien und Ergebnisse für prämenopausale primäre Brustkrebs-Patientinnen mit einem mittlerem und hohem Rezidivrisiko (CLEAR B)

54. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

57. CAPTOR-BC – Umfassende Analyse der räumlichen, zeitlichen und molekularen Muster zur Vorhersage der Wirksamkeit und Resistenz von Ribociclib bei Patientinnen mit fortgeschrittenem Brustkrebs.

58. Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.

63. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

64. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

67. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

72. 132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial

73. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

74. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

75. 122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib

76. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

81. Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05)

82. 66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto

83. 17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials

84. 21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)

86. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

89. Trastuzumab emtansine for residual invasive HER2-positive breast cancer

91. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

92. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

93. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Catalog

Books, media, physical & digital resources